Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Income (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Net Income for 6 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • For Q3 2025, Net Income changed N/A year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$4.1 million, changed N/A, while the annual FY2023 figure was $7.3 million, 128.38% up from the prior year.
  • Net Income hit -$1.0 million in Q3 2025 for Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Across five years, Net Income topped out at $13.5 million in Q3 2023 and bottomed at -$16.2 million in Q2 2021.
  • Average Net Income over 4 years is -$6.2 million, with a median of -$4.9 million recorded in 2022.
  • Year-over-year, Net Income rose 3.07% in 2022 and then surged 321.28% in 2023.
  • Cyclerion Therapeutics' Net Income stood at -$14.3 million in 2021, then skyrocketed by 79.82% to -$2.9 million in 2022, then soared by 565.74% to $13.5 million in 2023, then tumbled by 107.47% to -$1.0 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$1.0 million, -$1.7 million, and -$1.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.